Literature DB >> 18825588

Diversity of mucosa-associated microbiota in active and inactive ulcerative colitis.

Jun Nishikawa1, Takahiko Kudo, Shinji Sakata, Yoshimi Benno, Toshiro Sugiyama.   

Abstract

OBJECTIVE: Recent findings indicate that bacteria play an important role in the pathogenesis of inflammatory bowel disease (IBD). However, the exact role of bacteria in ulcerative colitis (UC) has still to be elucidated. The objective of the study was to investigate the potential differences in the intestinal microbiota between patients with UC and control subjects, using terminal restriction fragment length polymorphism (T-RFLP) analysis of the mucosa-associated microbiota from UC patients and non-IBD controls.
MATERIAL AND METHODS: Nine active UC patients and 11 non-IBD controls were included in the study. Seven patients with active UC who entered into the inactive phase after antibiotic combination treatment were also classified as patients with inactive UC. Mucosa-associated microbiota was compared between non-IBD controls and UC patients using T-RFLP analysis. Microbiota in both the active and inactive phase was also analyzed in UC patients receiving antibiotic treatment.
RESULTS: T-RFLP patterns of mucosa-associated microbiota differed between active UC patients and non-IBD controls. Microbial compositions of active UC patients were significantly less diverse. The difference resulted from loss of commensals. From the viewpoint of disease activity before and after antibiotic combination treatment, T-RFLP patterns were also different between the active and inactive phases in the identical patients. Inactive UC patients possessed more diverse microbial compositions. No specific terminal restriction fragments were observed in UC patients.
CONCLUSIONS: T-RFLP analysis showed that the mucosa-associated microbiota of patients with active UC differed from that of non-IBD controls. Active UC patients possessed significantly fewer diverse microbial compositions.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 18825588     DOI: 10.1080/00365520802433231

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  46 in total

1.  Reduced diversity and imbalance of fecal microbiota in patients with ulcerative colitis.

Authors:  Hideyuki Nemoto; Keiko Kataoka; Hideki Ishikawa; Kazue Ikata; Hideki Arimochi; Teruaki Iwasaki; Yoshinari Ohnishi; Tomomi Kuwahara; Koji Yasutomo
Journal:  Dig Dis Sci       Date:  2012-05-24       Impact factor: 3.199

Review 2.  The role of mucosal immunity and host genetics in defining intestinal commensal bacteria.

Authors:  Jonathan Hansen; Ajay Gulati; R Balfour Sartor
Journal:  Curr Opin Gastroenterol       Date:  2010-11       Impact factor: 3.287

3.  Multicenter analysis of fecal microbiota profiles in Japanese patients with Crohn's disease.

Authors:  Akira Andoh; Hiroyuki Kuzuoka; Tomoyuki Tsujikawa; Shiro Nakamura; Fumihito Hirai; Yasuo Suzuki; Toshiyuki Matsui; Yoshihide Fujiyama; Takayuki Matsumoto
Journal:  J Gastroenterol       Date:  2012-05-11       Impact factor: 7.527

4.  A randomised trial of sheathed versus standard forceps for obtaining uncontaminated biopsy specimens of microbiota from the terminal ileum.

Authors:  Maneesh Dave; Laura A Johnson; Seth T Walk; Vincent B Young; Ryan W Stidham; Meghana N Chaudhary; Jessica Funnell; Peter D R Higgins
Journal:  Gut       Date:  2011-02-11       Impact factor: 23.059

5.  Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis.

Authors:  Yasushi Yoshimatsu; Akihiro Yamada; Ryuichi Furukawa; Koji Sono; Aisaku Osamura; Kentaro Nakamura; Hiroshi Aoki; Yukiko Tsuda; Nobuo Hosoe; Nobuo Takada; Yasuo Suzuki
Journal:  World J Gastroenterol       Date:  2015-05-21       Impact factor: 5.742

6.  Ruminococcus gnavus total hip arthroplasty infection in a 62-year-old man with ulcerative colitis.

Authors:  Anne-Laure Roux; Faten El Sayed; Pascal Duffiet; Thomas Bauer; Beate Heym; Jean-Louis Gaillard; Jean-Louis Herrmann; Martin Rottman
Journal:  J Clin Microbiol       Date:  2015-01-28       Impact factor: 5.948

7.  Resveratrol modulates the gut microbiota to prevent murine colitis development through induction of Tregs and suppression of Th17 cells.

Authors:  Haider Rasheed Alrafas; Philip B Busbee; Mitzi Nagarkatti; Prakash S Nagarkatti
Journal:  J Leukoc Biol       Date:  2019-03-21       Impact factor: 4.962

8.  Molecular profiling of mucosal tissue associated microbiota in patients manifesting acute exacerbations and remission stage of ulcerative colitis.

Authors:  Sandeep A Walujkar; Shreyas V Kumbhare; Nachiket P Marathe; Dhrati V Patangia; Parimal S Lawate; Renu S Bharadwaj; Yogesh S Shouche
Journal:  World J Microbiol Biotechnol       Date:  2018-05-23       Impact factor: 3.312

9.  Pulmonary involvement: a rare extraintestinal manifestation of ulcerative colitis.

Authors:  Jun Nishikawa; Ayumu Hosokawa; Hiroshi Mihara; Ryuji Hayashi; Shigeharu Miwa; Tatsuhiko Kane; Sohachi Nanjo; Takayuki Ando; Haruka Fujinami; Shinya Kajiura; Masami Minemura; Toshiro Sugiyama
Journal:  Clin J Gastroenterol       Date:  2014-03-13

10.  Diet Modifies Colonic Microbiota and CD4+ T-Cell Repertoire to Induce Flares of Colitis in Mice With Myeloid-Cell Expression of Interleukin 23.

Authors:  Lili Chen; Zhengxiang He; Alina Cornelia Iuga; Sebastião N Martins Filho; Jeremiah J Faith; Jose C Clemente; Madhura Deshpande; Anitha Jayaprakash; Jean-Frederic Colombel; Juan J Lafaille; Ravi Sachidanandam; Glaucia C Furtado; Sergio A Lira
Journal:  Gastroenterology       Date:  2018-06-15       Impact factor: 22.682

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.